上海细胞治疗集团股份有限公司

I.CENTURY HLDG

RIVERINE CHINA

KOS TALENT GP

CHINA CBS INTL

NATURE ENERGY T

DIGIT HOLLYWOOD

REDCO HEALTHY

ZXZN QI-HOUSE

ASIA PIONEER

HUISHENG INTL

688520

<p>China Medical University Hospital and Ever Supreme Bio Technology have developed the world's first EXO 001 exosome platform, enabling in vivo multi-target CAR-T cell therapy for solid tumors. This breakthrough technology shows significant preclinical efficacy, including complete tumor eradication in animal models of colorectal, pancreatic, and malignant brain cancers. EXO 001 allows for direct genetic programming of T cells within the body, overcoming limitations of traditional CAR-T therapies. The platform offers advantages such as scalable manufacturing, cost reduction, and potential for long-term anti-tumor immunity, positioning it as a competitive solution in the global CAR-T landscape.</p>

prnewswire

Sinocelltech

02:28 ETWorld-First EXO 001 Exosome Platform Enables In Vivo Multi-Target CAR-T for Solid Tumors

上海细胞治疗集团股份有限公司(N24041.HK)

02:28 ETWorld-First EXO 001 Exosome Platform Enables In Vivo Multi-Target CAR-T for Solid Tumors